What happened with BBIO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
BridgeBio Pharma’s commercial business centers on acoramidis, sold in the United States as Attruby. This oral medicine is approved for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM. U.S. Attruby sales provide most of the company’s revenue. Patient access depends heavily on government and private insurance coverage, particularly Medicare and Medicaid.
The same drug is sold internationally as Beyonttra. Bayer holds European commercial rights and Alexion holds Japanese rights; BridgeBio earns licensing and milestone payments from these arrangements, plus royalties tied to the partners’ sales. It also sells directly in certain other international markets. The business therefore depends substantially on the same medicine, with Bayer and Alexion responsible for reaching patients in their licensed markets.
BridgeBio also develops other medicines for genetic diseases, many of them rare, with candidates still in preclinical research or clinical trials. Those candidates need regulatory approval before commercial sale. BridgeBio owns no manufacturing facilities and relies entirely on outside manufacturers for both marketed medicines and development supplies; its disclosed commercial supply arrangements have relied on one primary drug-product supplier.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
BridgeBio’s results hinge on Attruby winning patients from ATTR-CM rivals and on overseas acoramidis sales, especially through Bayer, its European partner paying substantial milestones and tiered royalties.
Pfizer competes directly for the patients buying BridgeBio’s Attruby and Beyonttra: its Vyndaqel and Vyndamax are also oral treatments for ATTR cardiomyopathy. Sales of those two Pfizer drugs show how the established rival is holding up against BridgeBio’s treatment.
Alnylam Pharmaceuticals competes with BridgeBio’s Attruby for ATTR cardiomyopathy patients through AMVUTTRA, making its pricing and patient uptake relevant to BridgeBio’s main product. Attruby’s lower U.S. list price and pill format are differences Alnylam says could limit AMVUTTRA’s market share and net product revenue.
Intellia Therapeutics could challenge BridgeBio’s long-term acoramidis treatment with nex-z, a gene-editing treatment being developed for ATTR amyloidosis. Its Phase 3 results are the news to watch for this potential rival to Attruby.
Ionis Pharmaceuticals’ WAINUA business and ATTR-CM development program compete or could compete with BridgeBio’s acoramidis for people with transthyretin amyloidosis. Ionis sells WAINUA jointly with AstraZeneca in the U.S.; its Phase 3 ATTR-CM program is the clearest development to watch for future competition with Attruby.
AstraZeneca both competes with BridgeBio and pays it: it jointly sells and develops the ATTR rival WAINUA with Ionis, while its Alexion subsidiary holds rights to sell BridgeBio’s Beyonttra in Japan. Alexion pays milestones and royalties on sales, tying Japanese Beyonttra commercialization to BridgeBio’s revenue.
BioMarin already sells Voxzogo for achondroplasia, the market BridgeBio hopes to enter with its late-stage oral treatment infigratinib. BioMarin’s Voxzogo net product revenue reached $926.9 million in 2025, giving a concrete measure of the established product BridgeBio would face if infigratinib is approved.
Ascendis Pharma’s TransCon CNP targets children with achondroplasia, the same patient group BridgeBio is pursuing with infigratinib, but through a different treatment mechanism. TransCon CNP was under review in the U.S. and EU, making those regulatory decisions worth watching for BridgeBio’s prospective competition.
Tyra Biosciences and BridgeBio are developing competing pills for achondroplasia that block FGFR signaling, putting their skeletal-dysplasia programs head to head. Watch progress in Tyra’s achondroplasia program, TYRA-300, rather than its cancer programs when assessing the threat to BridgeBio’s infigratinib.
BioMarin Pharmaceuticals Inc earningsBMRN
BioMarin’s report will show how Voxzogo is selling to people with achondroplasia, giving BridgeBio Pharma a read on the established rival and market its prospective oral treatment infigratinib would face.
Look at Voxzogo product sales, not BioMarin’s total revenue. Continued growth would show real demand in this treatment market, but also that BridgeBio would need to win patients from an established product if infigratinib is approved. Flat or falling sales could point to weaker market demand or adoption—not necessarily an opening BridgeBio can easily capture.
BridgeBio Pharma, Inc. earningsThis company
BridgeBio Pharma’s report will show whether U.S. Attruby sales can become the main engine of revenue growth, reducing reliance on more variable licensing and milestone income.
Separate product revenue from license and services revenue and royalties. Continued growth in product revenue would show broader U.S. uptake of Attruby; if product growth slows while partner-related revenue props up the total, growth depends more on partner sales, milestones or revenue recognition. Then consider operating cash outflow: sustained Attruby sales would help support the company’s substantial research and operating costs.
Fed Interest Rate Decision
BridgeBio’s substantial debt and possible need for new financing make the Fed’s decision on short-term borrowing rates relevant to what it pays to fund operations and refinance debt.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could make new or refinanced borrowing more expensive for BridgeBio, adding pressure if changing plans require it to seek funding sooner.
If it comes in below expectations
Lower rates could reduce the cost of new or refinanced borrowing for BridgeBio, easing funding pressure if it needs financing sooner than planned.
Alnylam Pharmaceuticals, Inc. earningsALNY
Alnylam Pharmaceuticals’ report will show how AMVUTTRA is selling to people with ATTR cardiomyopathy, giving BridgeBio Pharma a read on demand for a rival treatment in the same market.
Focus on AMVUTTRA’s sales trend, not Alnylam Pharmaceuticals’ total revenue as a proxy for the drug. Rising sales would show growing demand for this competing treatment and could mean more pressure on Attruby to win the same patients; falling sales would suggest this source of competition is not strengthening, but would not prove patients are switching to Attruby.
AstraZeneca PLC earningsAZN
AstraZeneca’s report may show how its Alexion unit is selling Beyonttra in Japan, giving BridgeBio Pharma a read on this partner-led source of sales and royalty revenue.
Look for disclosed Japanese Beyonttra sales or commercialization progress from AstraZeneca’s Alexion unit; AstraZeneca’s group-wide sales cannot stand in for those figures. Clear progress would strengthen the case for royalties to BridgeBio from partner sales. If disclosure is absent or progress limited, this revenue channel remains hard to assess—overall AstraZeneca growth would not establish Beyonttra growth.
